Related Experiment Videos
[Surveillance of susceptibility of clinical isolates to panipenem between 2000 and 2003]
Tomomi Abe1, Tetsufumi Koga, Yuki Sato
1Biological Research Laboratories, Sankyo Co., Ltd.
Abstract:
For the post-marketing surveillance of panipenem/betamipron (PAPM/BP, Carbenin), MICs of injectable beta-lactam antibacterials including PAPM against clinical isolates from 15 medical institutions all over Japan are measured yearly and the incidence rates of resistance in various species are also evaluated. In the first surveillance from June 2000 to March 2001, 1,356 isolates of 28 species were tested, 1,221 isolates of the same 28 species were tested in the second surveillance from April 2001 to March 2002, and 1,403 isolates of the same 28 species were tested in the third surveillance from April 2002 to March 2003. No remarkable changes in the activity of PAPM were observed in these surveillances spanning three years. The activity of PAPM in this study was comparable to that in the studies conducted before Carbenin was launched. This result suggests that PAPM still maintains potent activity. In these surveillances spanning three years, the incidence rates of resistance in various species were as follows (2000.6-2001.3 --> 2001.4-2002.3 --> 2002.4-2003.3): methicillin-resistant Staphylococcus aureus (39.3% --> 43.9% --> 47.3%), penicillin-intermediate Streptococcus pneumoniae (48.9% --> 44.2% --> 25.7%), penicillin-resistant S. pneumoniae (PRSP, 13.8% --> 26.3% --> 43.2%), extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (0.9% --> 0% --> 1.4%), ESBL-producing Klebsiella pneumoniae (3.4% --> 1.3% --> 3.1%), beta-lactamase-producing Haemophilus influenzae (19.2% --> 8.9% --> 42.9%), beta-lactamase-negative ampicillin-resistant H. influenzae (BLNAR, 22.1% --> 30.7% --> 33.0%), and metallo-beta-lactamase-producing Pseudomonas aeruginosa (1.0% --> 4.4% --> 1.0%). PAPM showed the most potent activity among tested drugs against PRSP, whose incidence rate increased notably. BLNAR, whose incidence rates also increased, exhibited low susceptibility to all tested drugs and metallo-beta-lactamase-producing P. aeruginosa also exhibited high resistance. The findings of this surveillance indicate that it is necessary to pay careful attention to the trends of resistant bacteria such as PRSP, BLNAR, and metallo-beta-lactamase producing strains.
Insights
Panipenem/betamipron (PAPM) maintains potent activity against clinical bacterial isolates in Japan. However, resistance rates for penicillin-resistant Streptococcus pneumoniae (PRSP) and beta-lactamase-negative ampicillin-resistant Haemophilus influenzae (BLNAR) are increasing.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Context:
- Post-marketing surveillance of panipenem/betamipron (PAPM) in Japan.
- Annual monitoring of Minimum Inhibitory Concentrations (MICs) and resistance rates for beta-lactam antibacterials.
- Data collected from 15 medical institutions over three years (2000-2003).
Purpose:
- To evaluate the ongoing activity and resistance trends of PAPM against various clinical bacterial isolates.
- To assess changes in resistance rates for key pathogens including methicillin-resistant Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, and Pseudomonas aeruginosa.
- To inform clinical practice regarding the efficacy of PAPM and the emergence of resistant strains.
Summary:
- PAPM demonstrated consistent potent activity across three years of surveillance, comparable to pre-launch levels.
- Significant increases in resistance were observed for penicillin-resistant Streptococcus pneumoniae (PRSP) and beta-lactamase-negative ampicillin-resistant Haemophilus influenzae (BLNAR).
- Metallo-beta-lactamase-producing Pseudomonas aeruginosa also showed high resistance, while extended-spectrum beta-lactamase (ESBL)-producing strains showed variable rates.
Impact:
- PAPM remains an effective therapeutic option, particularly against PRSP.
- The rising incidence of PRSP and BLNAR necessitates careful monitoring and strategic antibiotic use.
- Findings highlight the need for continued surveillance to track evolving antimicrobial resistance patterns.
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA